gabapentin has been researched along with Benign Neoplasms, Brain in 10 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs." | 5.29 | Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996) |
| "Patients undergoing craniotomy received either placebo (group D) or gabapentin (600 mg) (group GD) premedication orally, 2 hours before induction of anesthesia." | 5.17 | The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors. ( Misra, S; Parthasarathi, G; Vilanilam, GC, 2013) |
| "Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure." | 2.43 | Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005) |
| "Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs." | 1.29 | Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krishna, S | 1 |
| Choudhury, A | 1 |
| Keough, MB | 1 |
| Seo, K | 1 |
| Ni, L | 1 |
| Kakaizada, S | 1 |
| Lee, A | 1 |
| Aabedi, A | 1 |
| Popova, G | 1 |
| Lipkin, B | 1 |
| Cao, C | 1 |
| Nava Gonzales, C | 1 |
| Sudharshan, R | 1 |
| Egladyous, A | 1 |
| Almeida, N | 1 |
| Zhang, Y | 1 |
| Molinaro, AM | 1 |
| Venkatesh, HS | 1 |
| Daniel, AGS | 1 |
| Shamardani, K | 1 |
| Hyer, J | 1 |
| Chang, EF | 1 |
| Findlay, A | 1 |
| Phillips, JJ | 1 |
| Nagarajan, S | 1 |
| Raleigh, DR | 1 |
| Brang, D | 1 |
| Monje, M | 1 |
| Hervey-Jumper, SL | 1 |
| Corona-Ramos, JN | 1 |
| Déciga-Campos, M | 1 |
| Romero-Piña, M | 1 |
| Medina, LA | 1 |
| Martínez-Racine, I | 1 |
| Jaramillo-Morales, OA | 1 |
| García-López, P | 1 |
| López-Muñoz, FJ | 1 |
| Laghari, AA | 1 |
| Ahmed, SI | 1 |
| Qadeer, N | 1 |
| Shamim, MS | 1 |
| Mari, Z | 1 |
| Rosenthal, LS | 1 |
| Darwin, KC | 1 |
| Hallett, M | 1 |
| Jinnah, HA | 1 |
| Misra, S | 2 |
| Parthasarathi, G | 1 |
| Vilanilam, GC | 1 |
| Crespo Pérez, L | 1 |
| Moreira Vicente, V | 1 |
| Cano Ruiz, A | 1 |
| Gobernado Serrano, JM | 1 |
| Cobo Ibañez, N | 1 |
| Milicua Salamero, JM | 1 |
| Koshy, T | 1 |
| Unnikrishnan, KP | 1 |
| Suneel, PR | 1 |
| Chatterjee, N | 1 |
| Porzio, G | 1 |
| Aielli, F | 1 |
| Narducci, F | 1 |
| Varrassi, G | 1 |
| Ricevuto, E | 1 |
| Ficorella, C | 1 |
| Marchetti, P | 1 |
| van Breemen, MS | 1 |
| Vecht, CJ | 1 |
| Perry, JR | 1 |
| Sawka, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
4 reviews available for gabapentin and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
Clinical Reasoning: a 57-year-old man with jaw spasms.
Topics: Adrenergic Uptake Inhibitors; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids; | 2013 |
[Anticonvulsant hypersensitivity syndrome: an entity to be remembered].
Topics: Adolescent; Amines; Anemia, Hemolytic; Anticonvulsants; Astrocytoma; Brain Neoplasms; Carbamazepine; | 2009 |
Optimal seizure management in brain tumor patients.
Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I | 2005 |
2 trials available for gabapentin and Benign Neoplasms, Brain
| Article | Year |
|---|---|
The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors.
Topics: Adult; Amines; Anesthesia; Anti-Inflammatory Agents; Brain Neoplasms; Craniotomy; Cyclohexanecarboxy | 2013 |
Gabapentin premedication decreases the hemodynamic response to skull pin insertion in patients undergoing craniotomy.
Topics: Adolescent; Adult; Amines; Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Local; Blood P | 2011 |
4 other studies available for gabapentin and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Glioblastoma remodelling of human neural circuits decreases survival.
Topics: Biopsy; Brain; Brain Neoplasms; Cell Proliferation; Cognition; Disease Progression; Gabapentin; Glio | 2023 |
The Effect of Gabapentin and Tramadol in Cancer Pain Induced by Glioma Cell in Rat Femur.
Topics: Amines; Analgesics; Animals; Bone Neoplasms; Brain Neoplasms; Cancer Pain; Cell Line, Tumor; Cell Su | 2017 |
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Neoplasms; Carcinoma, Small Cell; Colonic Neoplasms; | 2003 |
Add-on gabapentin for refractory seizures in patients with brain tumours.
Topics: Acetates; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 1996 |